» Articles » PMID: 28942680

Brain Targeted Oral Delivery of Doxycycline Hydrochloride Encapsulated Tween 80 Coated Chitosan Nanoparticles Against Ketamine Induced Psychosis: Behavioral, Biochemical, Neurochemical and Histological Alterations in Mice

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2017 Sep 26
PMID 28942680
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

To develop statistically optimized brain targeted Tween 80 coated chitosan nanoparticulate formulation for oral delivery of doxycycline hydrochloride for the treatment of psychosis and to evaluate its protective effect on ketamine induced behavioral, biochemical, neurochemical and histological alterations in mice. 3 full factorial design was used to optimize the nanoparticulate formulation to minimize particle size and maximize entrapment efficiency, while independent variables chosen were concentration of chitosan and Tween 80. The optimized formulation was characterized by particle size, drug entrapment efficiency, Fourier transform infrared, Transmission electron microscopy analysis and drug release behavior. Pure doxycycline hydrochloride (25 and 50 mg/kg, p.o.) and optimized doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles (DCNP) (equivalent to 25 mg/kg doxycycline hydrochloride, p.o.) were explored against ketamine induced psychosis in mice. The experimental studies for DCNP, with mean particle size 237 nm and entrapment efficiency 78.16%, elucidated that the formulation successfully passed through blood brain barrier and exhibited significant antipsychotic activity. The underlying mechanism of action was further confirmed by behavioral, biochemical, neurochemical estimations and histopathological study. Significantly enhanced GABA and GSH level and diminished MDA, TNF-α and dopamine levels were observed after administration of DCNP at just half the dose of pure doxycycline hydrochloride, showing better penetration of doxycyline hydrochloride in the form of Tween 80 coated nanoparticles through blood brain barrier. This study demonstrates the hydrophilic drug doxycycline hydrochloride, loaded in Tween 80 coated chitosan nanoparticles, can be effectively brain targeted through oral delivery and therefore represents a suitable approach for the treatment of psychotic symptoms.

Citing Articles

Drug modifications: graphene oxide-chitosan loading enhanced anti-amoebic effects of pentamidine and doxycycline.

Jabri T, Daalah M, Alawfi B, Gul J, Ahmed U, Raza Shah M Parasitol Res. 2024; 123(11):387.

PMID: 39565414 DOI: 10.1007/s00436-024-08389-6.


Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective.

Conceicao M, Di Filippo L, Duarte J, Beserra F, Gremiao M, Chorilli M Brain Behav Immun Health. 2024; 42:100894.

PMID: 39525305 PMC: 11550769. DOI: 10.1016/j.bbih.2024.100894.


3-Acetyl coumarin alleviate neuroinflammatory responses and oxidative stress in aluminum chloride-induced Alzheimer's disease rat model.

Zeb Z, Sharif A, Akhtar B, Shahnaz Inflammopharmacology. 2024; 32(2):1371-1386.

PMID: 38448794 DOI: 10.1007/s10787-024-01434-x.


Doxycycline-Loaded Calcium Phosphate Nanoparticles with a Pectin Coat Can Ameliorate Lipopolysaccharide-Induced Neuroinflammation Via Enhancing AMPK.

Morsy S, Fathelbab M, El-Sayed N, El-Habashy S, Aly R, Harby S J Neuroimmune Pharmacol. 2024; 19(1):2.

PMID: 38236457 PMC: 10796490. DOI: 10.1007/s11481-024-10099-w.


Supramolecular Arrangement of Doxycycline with Sulfobutylether-β-Cyclodextrin: Impact on Nanostructuration with Chitosan, Drug Degradation and Antimicrobial Potency.

Carvalho Feitosa R, Souza Ribeiro Costa J, van Vliet Lima M, Sawa Akioka Ishikawa E, Muller K, Bonin Okasaki F Pharmaceutics. 2023; 15(4).

PMID: 37111770 PMC: 10144562. DOI: 10.3390/pharmaceutics15041285.


References
1.
LOWE I, Robins E, EYERMAN G . The fluorometric measurement of glutamic decarboxylase and its distribution in brain. J Neurochem. 1958; 3(1):8-18. DOI: 10.1111/j.1471-4159.1958.tb12604.x. View

2.
Chatterjee M, Verma P, Maurya R, Palit G . Evaluation of ethanol leaf extract of Ocimum sanctum in experimental models of anxiety and depression. Pharm Biol. 2011; 49(5):477-83. DOI: 10.3109/13880209.2010.523832. View

3.
Costa P, Sousa Lobo J . Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13(2):123-33. DOI: 10.1016/s0928-0987(01)00095-1. View

4.
Mandala Rayabandla S, Aithal K, Anandam A, Shavi G, Nayanabhirama U, Arumugam K . Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma. Drug Deliv. 2010; 17(3):103-13. DOI: 10.3109/10717540903548447. View

5.
Zugno A, Chipindo H, Volpato A, Budni J, Steckert A, de Oliveira M . Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience. 2013; 259:223-31. DOI: 10.1016/j.neuroscience.2013.11.049. View